Cannabotech

Cannabotech is a health-focused company originating in Israel that has combined two activities: preclinical pharmaceutical development using cannabinoids and medicinal mushroom extracts, and commercialization of consumer wellness products built around CBD and functional mushrooms. The company has described oncology and inflammatory-disease ambitions, with disclosed preclinical programs in pancreatic, colorectal, and breast cancer, while also marketing preventive-wellness products for stress, sleep, immunity, and skin health. Public and company sources identify Cannabotech as active, founded in 2019, and associated with the Tel Aviv market under the symbol CNTC, although business-profile sources also indicate the company has been referred to more recently as PsyRx CNS Bio-Tech. Its consumer product line emphasizes the proprietary M2CBD formulation that combines hemp-derived CBD with functional mushrooms such as reishi and lion's mane. Overall, Cannabotech appears to be a small, early-stage cannabinoid-and-mushroom therapeutics and wellness company rather than a clinically advanced drug developer.